However, genetic aberrations in TP53 are very common in cancer, and the extent of these TP53 mutations can be imagined by the fact that approximately 75–90% of PanCa patients harbor TP53 mutations [61], and there is no standard-of-care therapy for the treatment of mutated TP53. The gene discussed is TP53; the disease is cancer.